Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Improved ability to work after one year of natalizumab treatment in multiple sclerosis. Analysis of disease-specific and work-related factors that influence the effect of treatment.
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.
Focused suggestion with somatic anchoring technique: rapid self-hypnosis for pain management.
Early pathological alterations of lower lumbar cords detected by ultrahigh-field MRI in a mouse multiple sclerosis model.
An observational study to assess persistence, adherence, quality of life, and treatment satisfaction in patients beginning therapy with the Avonex® PEN™ (PERSIST)
Multiple sclerosis and progressive resistance training: a systematic review.
Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis.
[Multiple sclerosis : actuality and therapeutic prospects].
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.
Santhera enters agreement with Columbia University to investigate additional potential of Catena® in MELAS
Evidence-based guideline: Assessment and management of psychiatric disorders in individuals with MS: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
Involvement of oxidative stress on the impairment of energy metabolism induced by A beta peptides on PC12 cells: protection by antioxidants.
Unprovoked seizures in multiple sclerosis and systemic lupus erythematosus: A population-based case-control study.
Anejaculatory infertility due to multiple sclerosis.
Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation.
Psychotherapeutic and psychosocial interventions for managing stress in multiple sclerosis: the contribution of mindfulness-based interventions.
Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis.
Estimation of the effect of dalfampridine on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40mg three-times weekly versus 20mg daily in patients with relapsing-remitting multiple sclerosis.
Amiloride HCI Tablets, USP 5 mg
The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia.
Long-term follow-up of vanishing tumors in the brain: How should a lesion mimicking primary CNS lymphoma be managed?
Two Years Follow up of Domain Specific Cognitive Training in Relapsing Remitting Multiple Sclerosis: A Randomized Clinical Trial.
A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JC virus testing.
Physical Activity Behavior Change in Persons With Neurologic Disorders: Overview and Examples From Parkinson Disease and Multiple Sclerosis.

Pages